Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of BI 1181181 in Healthy Volunteers
NCT02044406Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jan 2014
- Primary completion
- Sep 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of BI 1181181 in Alzheimer's disease (AD) (2 arms), sponsored by Boehringer Ingelheim. Primary endpoints: Number (%) of subjects with drug-related adverse events, Area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point and 1 more. Started Jan 2014; status: completed.
02
Drugs
BI 1181181
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT02044406.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02044406.